The 10-year Survival Analysis of Radiofrequency Ablation for Solitary                     Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent                     HCC

Bai, Xiu-Mei; Cui, Ming; Yang, Wei; Wang, Hong; Wang, Song; Zhang, Zhongyi; Wu, Wei; Chen, Minhua; Yan, Kun; Goldberg, S. Nahum

doi:10.1148/radiol.2021200153

Cited by 61 publications

(45 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiofrequency ablation has emerged as an important alternative treatment to surgery for HCC ( 23 ). In this study, there were no significant differences in complete ablation rate, total tumor recurrence rate, and perioperative complications between the PRFA and SRFA groups.…”

Section: Discussionmentioning

confidence: 99%

Meta-analysis of Percutaneous vs. Surgical Approaches Radiofrequency Ablation in Hepatocellular Carcinoma

Huang

Liu

et al. 2022

Front. Surg.

View full text Add to dashboard Cite

Background: Radiofrequency ablation (RFA) is a curative modality for hepatocellular carcinoma (HCC) patients who are not suitable for resection. It remains controversial whether a surgical or percutaneous approach is more appropriate for HCC.Method: A search was performed on the PubMed, Web of Science, Embase, and Cochrane Library databases from the date of database inception until April 17, 2021. Studies reporting outcomes of comparisons between surgical RFA (SRFA) and percutaneous RFA (PRFA) were included in this study. The meta-analysis was performed using the Review Manager 5.3 and Stata 12.0 software.Result: A total of 10 retrospective studies containing 12 cohorts, involving 740 patients in the PRFA group and 512 patients in the SRFA group, were selected. Although the tumor size in PRFA group was smaller than the SRFA group (p = 0.007), there was no significant difference in complete ablation rate between the SRFA and PRFA groups (95.63% and 97.33%, respectively; Odds ratio [OR], 0.56; 95% confidence intervals [CI], 0.26–1.24; p = 0.15). However, the SRFA group showed a significantly lower local tumor recurrence than the PRFA group in the sensitivity analysis (28.7% in the PRFA group and 21.79% in the SRFA group, respectively; OR, 1.84; 95% CI, 1.14–2.95; p = 0.01). Pooled analysis data showed that the rate of severe perioperative complications did not differ significantly between the PRFA and SRFA groups (14.28% and 12.11%, respectively; OR, 1.30; 95% CI, 0.67-2.53; p = 0.44). There was no significant difference in the 1-, 3-, and 5-year overall survival rates, as well as the 1- and 3-year disease-free survival (DFS) between the PRFA and SRFA groups. The 5-year DFS of the PRFA group was significantly lower than the SRFA group (hazard ratio 0.73; 95% CI 0.54–0.99).Conclusion: Based on our meta-analysis, the surgical route was superior to PRFA in terms of local control rate. Furthermore, the surgical approach did not increase the risk of major complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Meta-analysis of Percutaneous vs. Surgical Approaches Radiofrequency Ablation in Hepatocellular Carcinoma

Huang

Liu

et al. 2022

Front. Surg.

View full text Add to dashboard Cite

show abstract

“…With respect to the number of tumors (HR = 14.684, 95% CI: 1.099À196.215, p = 0.042), logistic regression analysis revealed that patients with more than one liver cancer lesion are more likely to have early recurrence, which is similar to the results of several other studies regarding the relationship between multiple tumors and early recurrence. Some researchers (Geller et al 2006;Kim et al 2013;Bai et al 2021) believe that this is related to the multicenter origin of tumors. Patients with numerous tumors are more likely to develop micrometastases than patients with single tumors (Geller et al 2006).…”

Section: Discussionmentioning

confidence: 99%

Prediction Model and Nomogram of Early Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation Based on Logistic Regression Analysis

et al. 2022

Ultrasound in Medicine & Biology

View full text Add to dashboard Cite

“…Increasing evidence has shown that iRFA could incite an immune response and tumor progression and recurrence at the periablational "red zone" [9,11,12,[18][19][20]29]. Due to the unavailability of human HCC tissue samples after RFA, the relevant viewpoints established with the research of animal models and human peripheral blood remain to be supported by deeper rationale and reliable evidence.…”

Section: Discussionmentioning

confidence: 99%

“…However, RFA is not favored in cases with tumors larger than 2 cm, as this group has a lower rate of complete response and a higher recurrence rate than the group with smaller tumors [8]. Multiple studies have demonstrated that several clinical characteristics of tumor-like size, poorly de ned HCC margins, and location of the tumor near the portal vein branches, potentially resulting in incomplete RFA (iRFA), are signi cant risk factors for early local recurrence (<2 years) of HCC [9,10]. Moreover, two retrospective cohort studies [11,12] also con rmed that iRFA was signi cantly related to distant recurrence as well as local recurrence.…”

Section: Introductionmentioning

confidence: 99%

Integrated proteogenomic characterization and immune response evaluation reveal an imbalanced hepatocellular carcinoma microenvironment induced by incomplete radiofrequency ablation

Duan

Cui

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Efforts to precisely assess tumor-specific T-cell immune responses capable of mediating imbalanced hepatocellular carcinoma (HCC) ecosystems after incomplete radiofrequency ablation (iRFA) still face major challenges. Here, we assessed the immune response and performed transcriptomic and proteomic analyses in patients with HCC following iRFA. Methods: Peripheral blood and tissue samples were collected from HCC patients who underwent RFA. Multiplex immunostaining and flow cytometry were used to assess the local and systemic immune response. Differentially expressed genes (DEGs) and differentially expressed proteins (DEPs) were explored via transcriptomic and proteogenomic analyses. The ability of proteinase-3 (PRTN3) to predict overall survival (OS) was assessed in HCC patients with early recurrence after RFA. Results: Multiplex immunostaining revealed no immediate significant change in local immune cell counts. Flow cytometry analysis showed that the levels of CD4+ T cells, CD4+CD8+ T cells, and CD4+CD25+CD127- Treg cells were significantly increased, while the levels of CD16+CD56+ natural killer cells were significantly decreased on day 5 after cRFA (P<0.05). Transcriptomics and proteomics allow the identification of hundreds of DEGs and DEPs. Pathways related to immunoinflammation response, cancer progression and metabolism were found to be dysregulated at the transcriptomic and proteomic levels. Proteinase 3 (PRTN3) was observed to be persistently upregulated at the gene and protein levels and closely associated with the OS of early recurrent HCC following RFA. Conclusion: This study provides a comprehensive overview of the immune response and transcriptomic and proteogenomic landscapes of HCC milieus, revealing the mechanisms involved in the iRFA-induced immune response and tumor progression. Trial registration: ChiCTR2200055606, http://www.chictr.org.cn/showproj.aspx?proj=32588.

show abstract

The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC

Cited by 61 publications

References 27 publications

Meta-analysis of Percutaneous vs. Surgical Approaches Radiofrequency Ablation in Hepatocellular Carcinoma

Meta-analysis of Percutaneous vs. Surgical Approaches Radiofrequency Ablation in Hepatocellular Carcinoma

Prediction Model and Nomogram of Early Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation Based on Logistic Regression Analysis

Integrated proteogenomic characterization and immune response evaluation reveal an imbalanced hepatocellular carcinoma microenvironment induced by incomplete radiofrequency ablation

Contact Info

Product

Resources

About